Publications of Uwe Möginger
All genres
Journal Article (6)
2018
Journal Article
8, 70 (2018)
Alterations of the human skin N- and O-glycome in basal- and squamous cell carcinoma. Frontiers in Oncology 2016
Journal Article
76 (2), pp. 403 - 417 (2016)
An anti-EGFR IgA that displays improved pharmacokinetics and myeloid effector cell engagement in vivo. Cancer Research
Journal Article
6, 20488 (2016)
Cross Reactive Material 197 glycoconjugate vaccines contain privileged conjugation sites. Scientific Reports 2014
Journal Article
101, pp. 205 - 216 (2014)
Proteomics on porcine haptoglobin and IgG/IgA show protein species distribution and glycosylation pattern to remain similar in PCV2-SD infection. Journal of Proteomics 2013
Journal Article
12 (10), pp. 2935 - 2951 (2013)
Interlaboratory study on differential analysis of protein glycosylation by mass spectrometry: the ABRF glycoprotein research multi-institutional study 2012. Molecular and Cellular Proteomics
Journal Article
11 (33), pp. 5399 - 5403 (2013)
β(3R3)-peptides: design and synthesis of novel peptidomimetics and their self-assembling properties at the air-water interface. Organic & Biomolecular Chemistry Meeting Abstract (3)
2016
Meeting Abstract
39 (Suppl. 3), P276, pp. 83 - 84. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Leipzig, October 14, 2016 - October 18, 2016. Karger, Basel, Schweiz (2016)
Glyco- and Fc engineering of IgA antibodies for cancer immunotherapy improved pharmacokinetics & myeloid effector cell engagement. In Oncology Research and Treatment,
Meeting Abstract
69, 440, p. S144. Pergamon, Oxford, UK (2016)
Improvement of pharmacokinetics and myeloid effector cell engagement in vivo by Fc-engineering of IgA antibody against the epidermal growth factor receptor. In European Journal of Cancer, 2015
Meeting Abstract
33 supplement Ed., abstract 3037. 2015 ASCO Annual Meeting. Grune & Stratton, New York, NY (2015)
Pharmacokinetics and myeloid effector cell engagement of an engineered IgA antibody against the epidermal growth factor receptor. In Journal of Clinical Oncology,